Invalid Nucleic Acid Test Results May Limit Deceased Donor Organ Utilization
Transplant Infectious Disease · 2026
DOI: 10.1111/tid.70247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Sara Dionne und 5 weiteren Autor:innen. Beteiligte Einrichtung: Eurofins Donor & Product Testing, LLC, Centennial, Colorado, USA. Hauptthemen laut MEDLINE: Tissue Donors, Organ Transplantation, Donor Selection, Tissue and Organ Procurement. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Nucleic acid testing (NAT) is essential for detecting transmissible viral infections in deceased organ donors and guiding safe organ allocation. However, invalid discriminatory NAT (dNAT) results may lead to unnecessary donor exclusion and reduced organ availability.
Methods
We performed a retrospective analysis of HIV‐1/2, HBV, and HCV NAT results from deceased organ donors in the United States. Donor specimens were tested at eleven laboratories using FDA‐approved donor screening assays. Donor serologic results and organ utilization outcomes were reviewed to evaluate the clinical impact of invalid dNAT results.
Results
Invalid dNAT results occurred in 0.027% of donor cases ( n = 27), predominantly in cases suggestive of HCV infection ( n = 22). Although infrequent, these cases had a disproportionate impact on organ utilization. Serologic findings frequently supported true infection despite unresolved NAT results. Repeat testing did not resolve these cases and extended result reporting times by a median of 22 h. In 30% of cases ( n = 6) in which organ utilization was available, organs were not transplanted, reflecting uncertainty in infectious risk assessment.
Conclusion
Although rare, invalid dNAT results have clinical and operational consequences, contributing to delays, conservative donor classification, and reduced organ utilization. These findings highlight the need for standardized reporting of invalid results and access to rapid alternative confirmatory testing to support informed clinical decision‐making and reduce unnecessary organdiscard.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eurofins Donor & Product Testing, LLC, Centennial, Colorado, USA.
- New England Donor Services, Waltham, Massachusetts, USA.
- Sierra Donor Services, Sacramento, California, USA.
ORCID-Profile: Sara Dionne, Hillary Akana, Kaitlin Logue, Brenden O'Neale, Chris Curran, Sean VanSlyck
Zitieren
APA
Dionne, S., Akana, H., Logue, K., O'Neale, B., Curran, C., & VanSlyck, S. (2026). Invalid Nucleic Acid Test Results May Limit Deceased Donor Organ Utilization. Transplant Infectious Disease. https://doi.org/10.1111/tid.70247
Vancouver
Dionne S, Akana H, Logue K, O'Neale B, Curran C, VanSlyck S. Invalid Nucleic Acid Test Results May Limit Deceased Donor Organ Utilization. Transplant Infectious Disease. 2026. doi:10.1111/tid.70247
BibTeX
@article{Dionne2026,
author = {Dionne, Sara and Akana, Hillary and Logue, Kaitlin and O'Neale, Brenden and Curran, Chris and VanSlyck, Sean},
title = {Invalid Nucleic Acid Test Results May Limit Deceased Donor Organ Utilization},
journal = {Transplant Infectious Disease},
year = {2026},
doi = {10.1111/tid.70247}
}
EUVIMED